Navigation Links
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Date:11/11/2009

cense Application (BLA) for PROVENGE® (sipuleucel-T) to the U.S. Food and Drug Administration (FDA).
  • Elected Ian Clark and Pedro Granadillo to Board of Directors. Beginning Jan. 1, Mr. Clark will be chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group. Mr. Granadillo was most recently senior vice president of global manufacturing and human resources at Eli Lilly & Company.
  • "Submitting our BLA amendment is a milestone achievement for the organization," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon Corporation. "We look forward to working with the FDA to make PROVENGE available as quickly as possible to the many men who currently have few appealing treatment options."

    Conference Call Information

    Dendreon will host a conference call today at 1:30 p.m. PT, 4:30 p.m. ET. To access the live call, dial 1-888-516-2435 (domestic) or +1-719-457-2626 (international). The call will also be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 5275498. The replay will be available from 6:30 pm ET on Wednesday, November 11, until 11:59 pm ET on Friday, November 13. In addition, the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

    About PROVENGE

    PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of active cellular immunotherapies (ACIs) specifically designed to engage the patient's own
    '/>"/>

    SOURCE Dendreon Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Dendreon Completes Submission of Biologics License Application for PROVENGE
    2. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
    3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
    4. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
    5. Dendreon Reports Second Quarter 2009 Financial Results
    6. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
    7. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
    8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
    9. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
    10. Dendreon Announces Closing of Common Stock Offering
    11. Dendreon Announces Common Stock Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/26/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... advanced testing solutions for the detection of foodborne ... three months and full year ended December 31, ... for the quarter ended December 31, 2014 was ... quarter of 2013 and $1.5 million for the ...
    (Date:3/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... certain matters, including the appointment of auditors, its annual ... 2015 (the "Meeting") was adjourned, as previously disclosed on ... a.m. ( Toronto time). The date ... previous disclosed. The Meeting will reconvene at the offices ...
    (Date:3/26/2015)... DIEGO , March 26, 2015  BioNano Genomics, ... appointment of  Terry Salyer as chief commercial officer. ... highly effective, worldwide sales teams in life sciences. At ... ® System, a genome-mapping platform to assemble a ... investigate structural variations. To date, 32 institutions located in ...
    (Date:3/26/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today ... fiscal 2015, which ended Feb. 28, increased 13% to ... per share in the current quarter were $0.20, compared ... increased 17% over prior year to $24,142,000, or $0.65 ... for the same period a year ago. ...
    Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
    ... BioSpace , the leading life sciences employment and news ... marking the 7th edition. (Logo: ... organizations across the northwestern United States and western Canada. ... printed campaign map that is promoted online ...
    ... 2011 Funds Will be Used ... System Designed to Drive the Widespread Adoption of ... Fight Against Infectious Disease Biocartis, a ... systems designed to drive the widespread adoption of ...
    ... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), ... commercialization of its proprietary stent platform technology, today announced ... the Company,s board of directors and the former Chairman, ... Chairman of InspireMD,s Board of Directors, effective immediately. InspireMD ...
    Cached Biology Technology:BioSpace Spotlights Northwest's Life Science Community 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 3Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 4InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors 2InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors 3
    (Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
    (Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
    (Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
    Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
    ... poisonous ― but it might be used as an ... Tel Aviv University researcher claims. Prof. ... Sciences is investigating new ways for developing a novel ... of scorpions. These compounds have gone through millions of ...
    ... Bridget (Birgitta) of Sweden that has been kept in a ... study conducted at Uppsala University reveals that the two skulls, ... (Katarina), is not from maternally related individuals. Furthermore, dating show ... Bridget and Catherine lived. The findings are published in the ...
    ... will greatly benefit the U.S., say scientists in an ... of America (ESA), the nation,s largest organization of ecological ... and economic benefits of biofuel production, U.S. policies need ... ecosystems. In the report, scientists Virginia Dale, Keith ...
    Cached Biology News:Pinch away the pain 2Pinch away the pain 3The putative skull of St. Bridget can be questioned 2Beyond the corn field: Balancing fuel, food and biodiversity 2
    anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
    Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
    Request Info...
    ... KLH-conjugated, synthetic peptide corresponding ... of human BRAF-HDAC complex protein/Lysine-specific ... Quality Assurance Routinely evaluated ... 2 years at -20°C ...
    Biology Products: